Net Loss per Share

3 Months Ended

Mar. 31, 2025

Earnings Per Share [Abstract]

Net Loss per Share

Net Loss per Share

Potentially Dilutive Shares

The Company reported net losses for all periods presented, resulting in all potentially dilutive Common Stock equivalents being considered antidilutive and excluded from the calculation of net loss per share.

The table below presents the potentially dilutive shares that were excluded from the computation of diluted net loss per share of Common Stock attributable to Common Stock stockholders due to their antidilutive effect:

	Three Months Ended March 31,
	2025	2024
Shares issuable upon conversion of SPA Portfolio Notes	44,298,705	2,331,077
Shares issuable upon conversion of Unsecured Convertible Notes	1,809,969	390,601
Shares issuable upon exercise of equity classified SPA Portfolio Note warrants	15,238	13,968
Shares issuable upon exercise of liability classified SPA Portfolio Note warrants	35,244,948	—
Other warrants	5,776,657	228,482
Stock-based compensation awards – Options	2,514	2,731
Stock-based compensation awards – RSUs	155,134	21,439
Public warrants	2,453	2,453
Private warrants	12	12
	87,305,630	2,990,763